Observational studyJournal of registry management2025
The Burden of Cancers Associated with Hereditary Breast and Ovarian Cancer Syndrome, 2015-2019: A Population-based Cancer Registry Analysis.
Observational study in Journal of registry management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Hereditary breast and ovarian cancer syndrome (HBOCS) is an inherited condition that increases the risk of developing several types of cancer; however, the true burden of HBOCS-related cancers remains unclear at the population level. Methods: We used 2015-2019 breast and ovarian cancer data (N=55,437) from the New Jersey State Cancer Registry to estimate the age-adjusted incidence of HBOCS-related breast and ovarian cancers in New Jersey, overall and by county. Cancers meeting 5 HBOCS diagnostic characteristics selected from the 2021 National Comprehensive Cancer Network risk assessment guidelines were flagged as possibly being HBOCS-related and referred to as "possible-HBOCS (pHBOCS)." We evaluated the racial/ethnic and stage patterns of HBOCS cancers and compared them to all cancers to further characterize the HBOCS burden. Age-adjusted incidence rates (AAIR) per 100,000 population, rate ratios (RR), and 95% confidence intervals (CI) were computed using the Surveillance, Epidemiology, and End Results Program (SEER) *Stat Database. Results: We identified 12,679 pHBOCS cancers among NJ residents from 2015-2019. The female AAIR of pHBOCS breast and ovarian cancers was 50.6 per 100,000 population. The rates of pHBOCS varied by county, and pHBOCS county rates varied by race. Among Hispanic women, the incidence was significantly higher in Hunterdon County (AAIR 115, 95% CI:68.4-181.1) than statewide (AAIR 40.6, 95% CI:38.7-42.6). The pHBOCS incidence was significantly lower for Asian/Pacific Islander (RR=0.85, 95% CI:0.80-0.91), Hispanic (RR=0.74, 95% CI:0.70-0.79), and non-Hispanic Black women (RR=0.90 95% CI:0.85-0.95) than non-Hispanic White women. Compared to local-stage ovarian cancers, the incidence of distant-stage was significantly higher in the overall cancer population (RR=2.59, 95% CI:2.37-2.83) and the pHBOCS cancers (RR=3.22, 95% CI:2.93-3.55). The rate of regional-stage ovarian cancers was only significantly higher than local for the pHBOCS group (RR=1.21, 95% CI:1.08-1.36). Conclusions: This study can be used as a starting point for building a framework that better estimates the population burden of HBOCS cancers. Quantifying the HBOCS impact improves our understanding of the true burden. Due to data availability limitations, true estimates could not be calculated. Policies supporting population-level, genetic/family history data collection are needed to accurately quantify HBOCS incidence.
Indexed as
Identifiers
42110484PMC13151748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.